Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial

Journal of the European Academy of Dermatology and Venereology - United States

doi 10.1111/jdv.15793